NO964813D0 - Fremgangsmåte for stabilisering av duocarmycinderivater - Google Patents
Fremgangsmåte for stabilisering av duocarmycinderivaterInfo
- Publication number
- NO964813D0 NO964813D0 NO964813A NO964813A NO964813D0 NO 964813 D0 NO964813 D0 NO 964813D0 NO 964813 A NO964813 A NO 964813A NO 964813 A NO964813 A NO 964813A NO 964813 D0 NO964813 D0 NO 964813D0
- Authority
- NO
- Norway
- Prior art keywords
- pct
- duocarmycin derivatives
- sec
- image
- stabilization
- Prior art date
Links
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000005846 sugar alcohols Polymers 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Detergent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6106415A JPH07309761A (ja) | 1994-05-20 | 1994-05-20 | デュオカルマイシン誘導体の安定化法 |
PCT/JP1995/000962 WO1995031971A1 (en) | 1994-05-20 | 1995-05-19 | Method for stabilizing duocarmycin derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
NO964813D0 true NO964813D0 (no) | 1996-11-13 |
NO964813L NO964813L (no) | 1996-11-13 |
Family
ID=14433044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO964813A NO964813L (no) | 1994-05-20 | 1996-11-13 | Fremgangsmåte for stabilisering av duocarmycinderivater |
Country Status (17)
Country | Link |
---|---|
US (1) | US5703080A (no) |
EP (1) | EP0754030B1 (no) |
JP (1) | JPH07309761A (no) |
CN (1) | CN1148805A (no) |
AT (1) | ATE198149T1 (no) |
AU (1) | AU2455195A (no) |
BR (1) | BR9507640A (no) |
CA (1) | CA2190635A1 (no) |
CZ (1) | CZ338696A3 (no) |
DE (1) | DE69519667T2 (no) |
FI (1) | FI964624A0 (no) |
HU (1) | HUT78072A (no) |
NO (1) | NO964813L (no) |
NZ (1) | NZ285450A (no) |
PL (1) | PL317229A1 (no) |
SK (1) | SK148496A3 (no) |
WO (1) | WO1995031971A1 (no) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3532895A (en) * | 1994-09-30 | 1996-04-26 | Kyowa Hakko Kogyo Co. Ltd. | Antitumor agent |
CA2443694A1 (en) * | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
WO2002096910A1 (en) * | 2001-05-31 | 2002-12-05 | Medarex, Inc. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
ZA200507752B (en) * | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
BRPI0510909A2 (pt) | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
KR101335798B1 (ko) | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-cd19 항체 및 종양학에서 이의 용도 |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
CA2607281C (en) | 2005-05-05 | 2023-10-03 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
ES2389532T3 (es) | 2005-06-29 | 2012-10-29 | Threshold Pharmaceuticals, Inc. | Profármacos alquilantes de fosforamidato |
WO2007038658A2 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
CN101365679B (zh) | 2005-10-26 | 2012-11-14 | 梅达莱克斯公司 | 制备cc-1065类似物的方法和化合物 |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
KR101552735B1 (ko) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
WO2008074004A2 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
EP2114157B1 (en) * | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
CL2008000510A1 (es) | 2007-02-21 | 2008-08-22 | Medarex Inc | Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero. |
EP2737907A3 (en) | 2007-05-07 | 2014-11-05 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
KR101554753B1 (ko) | 2007-10-01 | 2015-09-22 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
JP5490714B2 (ja) * | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
WO2009073524A2 (en) * | 2007-11-30 | 2009-06-11 | Medarex, Inc. | Conjugates of anti-rg-1 antibodies |
US8192738B2 (en) | 2008-09-19 | 2012-06-05 | Medimmune, Llc | Targeted antibodies directed to DLL4 |
WO2010062171A2 (en) | 2008-11-03 | 2010-06-03 | Syntarga B.V. | Novel cc-1065 analogs and their conjugates |
BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
WO2010072740A2 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF |
JP5918129B2 (ja) | 2009-06-22 | 2016-05-18 | メディミューン,エルエルシー | 部位特異的共役のための操作されたFc領域 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
CA2789629A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
AU2011243294C1 (en) | 2010-04-21 | 2015-12-03 | Syntarga B.V. | Novel conjugates of CC-1065 analogs and bifunctional linkers |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
ES2640960T3 (es) | 2011-06-28 | 2017-11-07 | Oxford Biotherapeutics Ltd. | Anticuerpos para ADP-ribosil ciclasa 2 |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
AU2012323287B2 (en) | 2011-10-10 | 2018-02-01 | Xencor, Inc. | A method for purifying antibodies |
ES2721882T3 (es) | 2011-12-23 | 2019-08-06 | Pfizer | Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
DK2943511T3 (da) | 2013-01-14 | 2019-10-21 | Xencor Inc | Nye heterodimeriske proteiner |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
KR102561553B1 (ko) | 2013-03-15 | 2023-07-31 | 젠코어 인코포레이티드 | 이형이량체 단백질 |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10081682B2 (en) | 2013-10-11 | 2018-09-25 | Oxford Bio Therapeutics Ltd. | Conjugated antibodies against LY75 for the treatment of cancer |
SG11201605605SA (en) | 2014-01-10 | 2016-08-30 | Synthon Biopharmaceuticals Bv | Method for purifying cys-linked antibody-drug conjugates |
WO2015127685A1 (en) | 2014-02-28 | 2015-09-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
AU2015292326A1 (en) | 2014-07-24 | 2017-02-23 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
AU2015353409B2 (en) | 2014-11-26 | 2019-05-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
IL263542B1 (en) | 2016-06-14 | 2024-06-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
US10316088B2 (en) | 2016-06-28 | 2019-06-11 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
BR112019007288A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente |
AU2016429272A1 (en) | 2016-11-14 | 2019-05-02 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗pd−1配列を用いた二重特異性および単一特異性抗体 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3728302A1 (en) | 2017-12-19 | 2020-10-28 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
PE20211091A1 (es) | 2018-07-02 | 2021-06-14 | Amgen Inc | Proteina de union al antigeno anti-steap1 |
CN113195523A (zh) | 2018-10-03 | 2021-07-30 | Xencor股份有限公司 | IL-12异源二聚体Fc融合蛋白 |
JP2022523946A (ja) | 2019-03-01 | 2022-04-27 | ゼンコア インコーポレイテッド | Enpp3およびcd3に結合するヘテロ二量体抗体 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084468A (en) * | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
JP2510335B2 (ja) * | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Dc―88a誘導体 |
KR910014122A (ko) * | 1990-01-19 | 1991-08-31 | 디께다 가즈히꼬 | 에토포시드-2-디메틸아미노 화합물의 동결건조 제제 |
US5214065A (en) * | 1990-06-11 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Dc-89 derivatives |
JPH0669954B2 (ja) * | 1990-12-07 | 1994-09-07 | 吉富製薬株式会社 | 抗腫瘍組成物 |
EP0499130A1 (en) * | 1991-02-15 | 1992-08-19 | Kyowa Hakko Kogyo Co., Ltd. | DC-89 derivatives |
JP3608802B2 (ja) * | 1991-09-20 | 2005-01-12 | 第一サントリーファーマ株式会社 | 安定なカルシトニン医薬組成物及びその製造法 |
-
1994
- 1994-05-20 JP JP6106415A patent/JPH07309761A/ja active Pending
-
1995
- 1995-05-19 HU HU9603521A patent/HUT78072A/hu unknown
- 1995-05-19 WO PCT/JP1995/000962 patent/WO1995031971A1/en active IP Right Grant
- 1995-05-19 US US08/737,145 patent/US5703080A/en not_active Expired - Fee Related
- 1995-05-19 PL PL95317229A patent/PL317229A1/xx unknown
- 1995-05-19 NZ NZ285450A patent/NZ285450A/en unknown
- 1995-05-19 DE DE69519667T patent/DE69519667T2/de not_active Expired - Fee Related
- 1995-05-19 CZ CZ963386A patent/CZ338696A3/cs unknown
- 1995-05-19 SK SK1484-96A patent/SK148496A3/sk unknown
- 1995-05-19 BR BR9507640A patent/BR9507640A/pt not_active Application Discontinuation
- 1995-05-19 AT AT95918749T patent/ATE198149T1/de not_active IP Right Cessation
- 1995-05-19 EP EP95918749A patent/EP0754030B1/en not_active Expired - Lifetime
- 1995-05-19 AU AU24551/95A patent/AU2455195A/en not_active Abandoned
- 1995-05-19 CA CA002190635A patent/CA2190635A1/en not_active Abandoned
- 1995-05-19 CN CN95193164A patent/CN1148805A/zh active Pending
-
1996
- 1996-11-13 NO NO964813A patent/NO964813L/no unknown
- 1996-11-19 FI FI964624A patent/FI964624A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
US5703080A (en) | 1997-12-30 |
ATE198149T1 (de) | 2001-01-15 |
NZ285450A (en) | 1997-02-24 |
PL317229A1 (en) | 1997-03-17 |
CA2190635A1 (en) | 1995-11-30 |
DE69519667D1 (de) | 2001-01-25 |
HUT78072A (hu) | 1999-08-30 |
BR9507640A (pt) | 1997-08-19 |
FI964624A (fi) | 1996-11-19 |
SK148496A3 (en) | 1997-06-04 |
CN1148805A (zh) | 1997-04-30 |
FI964624A0 (fi) | 1996-11-19 |
MX9605694A (es) | 1998-05-31 |
WO1995031971A1 (en) | 1995-11-30 |
DE69519667T2 (de) | 2001-04-26 |
JPH07309761A (ja) | 1995-11-28 |
NO964813L (no) | 1996-11-13 |
EP0754030B1 (en) | 2000-12-20 |
AU2455195A (en) | 1995-12-18 |
EP0754030A1 (en) | 1997-01-22 |
HU9603521D0 (en) | 1997-03-28 |
CZ338696A3 (en) | 1997-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO964813D0 (no) | Fremgangsmåte for stabilisering av duocarmycinderivater | |
PL327169A1 (en) | Naphtyl-substituted derivatives of benzimidazole as anticoagulants | |
KR950700894A (ko) | 탁솔 유도체(Taxol derivatives) | |
DE69413542D1 (de) | Perhydroisoindolderivate als substanz p antagonisten | |
ES2132415T3 (es) | Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol. | |
AU8599091A (en) | Antimicrobial agents as well as substituted 2-cyclohexan-1-y1-amine derivatives and their preparation | |
ATE260658T1 (de) | Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen | |
AU699480B2 (en) | 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these | |
ATE247959T1 (de) | Nicht peptidische g-csf mimetika | |
CA2219359A1 (en) | Hydantoin derivatives as intermediates for pharmaceutical active compounds | |
DE69330601D1 (de) | Serotoninergische ergolin derivate | |
DE59304311D1 (de) | N-substituierte 3-azabicyclo[3.2.0]heptan-derivate als neuroleptika | |
DE59509186D1 (de) | N-substituierte azabicycloheptan-derivate als neuroleptika usw. | |
IL107520A0 (en) | Substituted ortho-ethenylphenylacetic acid derivatives and pharmaceutical compositions containing them | |
DE69318715D1 (de) | Pharmakologisch aktive alpha-(tertiär-aminoethyl)-phenylmethanol-derivate | |
SE9001592D0 (sv) | A therapeutical composition | |
AU4544096A (en) | New derivatives of glycylanilides, preparation and therapeutical application | |
RU96124085A (ru) | Способ стабилизации производных дуокармицина |